Participated · Equity · Mar 2022

Reynen Court operates a legal-technology platform that helps large law firms research, test, securely adopt and manage cloud-based software applications on infrastructure of their choice. The platform lets firms mix and match the applications they need to run their business in the cloud. Since its founding in 2017, a consortium of twenty of the largest global law firms has supported its development, and a second consortium of twenty-two banks and global corporations has joined to collaborate. More than 150 third-party application vendors are participating on or working toward participation on the platform. The company is based in Amsterdam and New York. It intends to use the new funding to expand operations and broaden its business reach.

Participated · Series D · Sep 2011

KYTHERA Biopharmaceuticals is a privately held, clinical-stage biotech focused on discovery, development and commercialization of novel prescription products for the aesthetic market. Its lead program is ATX-101, a first-in-class synthetic injectable being studied for reduction of submental (under‑the‑chin) fat. Clinical development to date includes seven clinical trials with more than 350 subjects, three randomized double-blind placebo-controlled Phase II studies and four Phase I studies; two Phase III randomized, double-blind, placebo-controlled studies are ongoing in Europe in collaboration with Bayer HealthCare’s dermatology unit Intendis. Intendis has licensed rights to ATX-101 outside the U.S. and Canada. KYTHERA plans to use proceeds from the financing to conduct U.S. Phase III trials for ATX-101 and projects starting U.S. Phase III late 2011 or early 2012. The company also maintains research programs in hair and fat biology, pigmentation modulation and facial contouring and has raised more than $108M across four private financing rounds.